06:11 AM EDT, 07/20/2026 (MT Newswires) -- SynAct Pharma (SYNACT.ST) secured a 100 million-krona financing facility and has drawn 50 million kronor through a convertible loan issue. The clinical-stage biotechnology company said Monday it will use the funding to bolster its financial position and advance its preparations for phase 3 development. It added that the balance will be utilized if and when it is strategically beneficial for the company.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.